First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Colaboración

Año: 2018

Aranda, E; Garcia-Alfonso, P; Benavides, M; Ruiz, AS; Guillen-Ponce, C; Safont, MJ; Alcaide, J; Gomez, A; Lopez, R; Manzano, JL; Urena, MM; Sastre, J; Rivera, F; Gravalos, C; Garcia, T; Martin-Valades, JI; Falco, E; Navalon, M; Flores, EG; Tapiador, AMG; Munoz, AML; Barrajon, E; Reboredo, M; Teijido, PG; Viudez, A; Cardenas, N; Diaz-Rubio, E

Título: EUROPEAN JOURNAL OF CANCER

• Q1